Global Information
회사소개 | 문의 | 위시리스트

세계의 동물 건강 시장

Animal Health Market Consolidation, 2019-2023: Who will not survive?

리서치사 Venture Planning Group
발행일 상품 코드 574428
페이지 정보 영문
가격
US $ 2,450 ₩ 2,900,000 PDF by E-mail (Local License)
US $ 4,500 ₩ 5,327,000 PDF by E-mail (Global License)


세계의 동물 건강 시장 Animal Health Market Consolidation, 2019-2023: Who will not survive?
발행일 : 페이지 정보 : 영문

세계 동물 건강(Animal Health) 시장의 최신 상황과 향후 전망에 대해 분석했으며, 현재 시장 규모·구조·특성, 향후 전망, 업계 재편 및 변용 가능성, 현재 시장 동향과 향후 영향, 주요 기업 개요와 사업 추진 상황, 각 기업의 향후 성장 및 시장 철수 가능성 등에 대해 정리하여 전해드립니다.

1. 목차 : 조사 내용

  • 세계의 동물 건강 시장 동정과 동향

2. 조사 대상 기업 개요

  • Bayer Animal Health
  • Boehringer Ingelheim
  • Ceva
  • Elanco Animal Health
  • Merck Animal Health
  • Phibro Animal Health
  • Virbac
  • Zoetis
LSH 17.11.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?

- How will the current trends affect the major market segments?

- Which companies will enter the market and which will not survive?

This new 15-page report from VPGMarketResearch analyzes strategies, marketing tactics and
technological know-how of the world's leading animal health companies, including:

  • Five-year forecasts for:

    - Major market segments

    - Key geographic regions

  • Assessment of major U.S. and international trends with potentially significant impact on the animal health industry during the next five years, including discussion of such issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics and other technologies.

    The company profiles include:

  • Specific business, new product development and marketing strategies.
  • Anticipated acquisitions, joint ventures and divestitures.
  • Major strengths and weaknesses.
  • Sales force size in the U.S. and other markets.
  • Promotional tactics.
  • Distribution approaches.
  • Product service and support.
  • Customer relations.
  • Internally developed and acquired animal health technologies, processes and related capabilities.
  • Proprietary technologies and patent litigations.
  • Contains 110 pages and 6 tables

    Table of Contents

    The Global Animal Health Market Dynamics and Trends

    • Strategic overview of the worldwide animal health market.
    • Five-year forecasts for major market segments and key geographic regions.
    • Assessment of major U.S. and international trends with potentially significant impact on the animal health industry during the next five years.
    • Pricing, industry consolidation, market globalization, growing R&D cost, and generics.
    • Advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics and other technologies.
    • Key market segments
    • Major geographic areas

    Company Profiles

    Bayer Animal Health

    • Considering selling animal health division
    • Plans to invest in Kiel
    • Rising demand for collars
    • Focusing on parasiticides and anti-infectives
    • Strong position in parasiticides
    • Animal health R&D
    • Worldwide marketing network
    • Emerging markets
    • Re-registering existing products
    • Present structure
    • Diverse businesses
    • Challenged by animal disease outbreaks
    • Europe's premier research organization
    • Animal health R&D
    • Crop science segment
    • Monsanto acquisition
    • Chairman Werner Baumann
    • Supervisory board

    Boehringer Ingelheim

    • Sales and growth
    • Animal health is one of the major pillars
    • Swine vaccine Ingelvac circoflex
    • Merial animal health
    • U.S. animal health market position
    • Promoting Eqvalan line
    • Seeking to reinforce position in livestock market
    • Strategies supported by collaborations
    • Merial R&D programs
    • Collaborative efforts
    • Porcine Reproductive and Respiratory Syndrome (PRRS)
    • Decentralized R&D

    Ceva

    • Sales, growth and R&D investment
    • Biomune, Phylaxia and French sites
    • 2016 acquisitions
    • Hatcher automation and in-ovo vaccination
    • India acquisition
    • Brazil--important strategic market
    • Merial swine vaccines acquisition

    Elanco Animal Health

    • Strong technological base
    • Fermentation and chemical synthesis
    • Strong base in antibiotics and anticoccidials
    • Expiration of patents caused restructuring
    • US marketing
    • Lilly Japan
    • Focused marketing strategies
    • Well-established relationship with customers
    • Multi-disciplinary business with diverse product portfolio
    • In the midst of strategic decisions
    • Stepping up efforts to curtail time to market
    • Could divest animal health
    • Changed product mix
    • Strategic collaborations
    • Broadening portfolio of companion animal medicines
    • Hard look at bottom line
    • CEO Dave Ricks

    Merck Animal Health

    • Sales and growth
    • Higher sales of Bravecto
    • Vallée acquisition
    • Extensive know-how in animal health
    • Sphereon technology
    • Expanding worldwide poultry business
    • Poultry biological research laboratories
    • Segmented poultry-product line
    • Mitigated generic competition
    • R&D productivity improving
    • Patents, economies of scale, and powerful intellectual base
    • Keytruda key to future

    Phibro Animal Health

    • Sales and growth
    • Extensive portfolio of antibiotics and antibacterials
    • Sales force, sales offices and distribution network
    • Animal health R&D facilities
    • Biotay acquisition

    Virbac

    • Sales and growth
    • Eli Lilly dog parasiticides acquisition
    • Product portfolio
    • Formulation know-how
    • Waltham nutrition products
    • Reorganized European distribution
    • Decentralized approach for food-producing animals
    • Benefitting from new companion animal products
    • Focusing on niche markets
    • Seeking expansion in the U.S.

    Zoetis

    • Majority of revenue from production animals
    • Largest market share in the industry
    • Poultry and swine revenue declining
    • Scale allows to use own sales force in emerging markets
    • Management continues cost-cutting efforts
    • Reassessing manufacturing infrastructure
    • CEO Juan Ramon Alaix
    • Market-leading position in emerging markets
    • Leading share in Asia-Pacific, Canada and Latin America
    • Fragmented customer base
    • Leading position in fastest-growing markets
    Back to Top
    전화 문의
    F A Q